ClinicalTrials.gg

Program

cotsiranib

Its studies are mostly in Cicatrix, Hypertrophic · Carcinoma, Basal Cell · Keloid · Carcinoma, Hepatocellular · Obesity, Abdominal, led by Sirnaomics.

Furthest: phase 2, since Oct 31, 201610 company-led studies, 1 open or runningNext primary completion: Jul 25, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sirnaomics101 open or runningphase 2since Oct 31, 2016Oct 31, 2016Jul 25, 2027phase 2 · NCT07677683

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 31, 2016First study: phase 2 study in Cicatrix, HypertrophicFirst studyNCT02956317 · 25 enrolled · United States
  2. Feb 26, 2020Phase 2 study in Bowen's DiseaseNCT04293679 · 25 enrolled · United States
  3. Dec 9, 2020Phase 2 study in Carcinoma, Basal CellNCT04669808 · 32 enrolled · United States
  4. Dec 15, 2020Phase 1 study in Carcinoma, HepatocellularNCT04676633 · 5 enrolled · United States
  5. Apr 8, 20212 phase 2 studiesNCT04844840, NCT04844983
  6. Dec 15, 2021Phase 2 study in Cicatrix, HypertrophicNCT05196373 · China
  7. Jun 8, 2022Phase 1 study in Obesity, AbdominalNCT05422378 · 8 enrolled · United States
  8. Jun 12, 2022Phase 2 study in Facial isSCCNCT05421013 · 9 enrolled · United States
  9. Jun 21, 2026Phase 2 study in Submental FullnessNCT07677683 · 30 planned · Australia

Ahead

  1. Jul 25, 2027Primary completion: phase 2 study in Submental FullnessNCT07677683

TargetBeta

PNP →read by rule
“A polypeptide nanoparticle (PNP)-based small interfering RNA (siRNA) therapeutic directed against transforming growth factor-beta 1 (TGF-beta 1) and cyclo-oxygenase-2 (COX-2), ”NCIt, by rule

Studies

All 10 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07677683Submental Fullness · Australia2RecruitingJul 25, 202730
NCT05421013Facial isSCC · United States2TerminatedMar 29, 20239
NCT05422378Obesity, Abdominal · United States1CompletedFeb 3, 20238
NCT05196373Cicatrix, Hypertrophic · China2WithdrawnJun 30, 20220
NCT04844983Squamous Intraepithelial Lesions · United States2CompletedAug 24, 202244
NCT04844840Keloid · United States2CompletedMay 17, 202329
NCT04676633Carcinoma, Hepatocellular · United States1CompletedJan 13, 20235
NCT04669808Carcinoma, Basal Cell · United States2CompletedFeb 9, 202332
NCT04293679Bowen's Disease · United States2CompletedOct 21, 202025
NCT02956317Cicatrix, Hypertrophic · United States2CompletedJan 201825

How it is read

Names in the registry

  • “STP705”, 10 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.